ISSN: 2167-7700
Chemotherapy: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

Origin of Cancer: Founder Clones

Shi-Ming Tu*
Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas MD Anderson Cancer Center, USA
*Corresponding Author : Shi Ming Tu
Department of Genitourinary Medical Oncology
Unit 1374, The University of Texas MD Anderson Cancer Center
1155 Pressler Street, Houston
TX 77030-3721, USA
Tel: 713-563-7268
Fax: 713-745-0827
E-mail: stu@mdanderson.org
Received October 16, 2012; Accepted October 18, 2012; Published October 21, 2012
Citation: Tu SM (2012) Origin of Cancer: Founder Clones. Chemotherapy 1:e115. doi:10.4172/2167-7700.1000e115
Copyright: © 2012 Tu SM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Chemotherapy: Open Access

The article by Walter et al. [1] provides some invaluable insights on the origin and nature of secondary acute myeloid leukemia. Because they used human tumor samples rather than animal models or cell lines, their results have immediate relevance. Importantly, studies like theirs may finally answer some fundamental questions about the origin of cancer.
The idea of a clonal origin of cancer is not new. But, to demonstrate this idea in relevant human cases is significant. Although they implied it, the authors did not address the phenotype of the founding clone. They cautiously mentioned that the founding clone must have retained the capacity for self-renewal. Whether the founding clone possesses “stemness” features and therefore, represents a cancer stem cell is unknown. Further, it remains unclear, whether the founding clone originates from disparate cells in a stem-cell hierarchy that give rise to different diseases with distinct clinical outcomes (e.g. UPN461282 and UPN266395 have survival times of 67 and 11 months from diagnosis, respectively). The stem-cell theory of cancers [2] could account for the apparent paradox that malignancies with worse clinical outcome have fewer mutations (6.7% versus 37.8%); their inherent stemness obviates the need to acquire more mutations to become malignant, because many stemness properties are also potential malignant characteristics.
With the Walter et al. [1] article, we have in our hands for the first time, clinical cases rather than experimental models that may reveal a stem-cell origin versus de-differentiation of cancers. The database they provided enables testing to see, whether a founding clone with stemness properties becomes aberrant by accumulating mutations, or a founding clone with somatic phenotypes becomes malignant by acquiring stemness properties. Even if both scenarios were possible, we would suspect that the two separate founding clones give rise to distinct diseases with different clinical courses.
Undoubtedly, the strength of this study lies in its focus on the genotype of the serial tumors. It would have been even more informative, if it had identified the phenotype of the founding clones. Ironically, the results of this study may signal a shift from our gene-centric view of cancer to a cell-centric view. Although genetic mutations are critical, the cellular context within which they occur is also paramount in our understanding of cancer. Otherwise, why are the vast majority of mutations in the current study considered to be random background mutations? [1]. Why would apparently similar tumors contain different mutations [3] and the same mutations be found in different tumors? [4]. I believe that a common link between the founding clones and the mutations they contain is the cell of origin.
Results of the study by Walter et al. [1] have important clinical implications, as far as personalized care is concerned. The authors correctly stated that treatments targeting the founding clone are likely to be more efficacious than those that do not target it. But, should we target the mutated genes within a cell or the aberrant cell itself? That is the ultimate question. Alas, when we target specific genetic mutations, we tend to ignore the proper cellular context. After all, there are tens, if not hundreds of genetic mutations within a complex web of redundant pathways, which remind us of the very cellular entity we have so far neglected. Consequently, when we target one mutation (e.g. PIK3Ca), the cell adapts and compensates by enhancing another aberrancy (e.g. c-Myc overexpression) [5]. In contrast, when we target an aberrant founder clone with its whole package of genetic mutations rather than the individual mutations themselves, we are simultaneously treating a whole system of molecular, intracellular, intercellular, and microenvironmental networks and pathways. I propose that personalized care will be more effective, if it targets a particular cellular entity rather than a specific genetic mutation within it.
References
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Acute Lymphoblastic Leukemia
Disc Acute Megakaryocytic Leukemia
Disc Acute Myelomonocytic Leukemia
Disc Acute Myleoid Leukemia
Disc Adenocarcinoma pancreas
Disc Advances in Alternative Lung Cancer Treatment
Disc Aleukemic Leukemia
Disc Anti-Cancer Drug
Disc Apoptosis
Disc Bone Cancer Stages
Disc Bone Marrow Cancer Survival
Disc Brain Tumor Treatment
Disc Cancer Science
Disc Cancer Therapies
Disc Cancer initiation and progression
Disc Cancer therapy
Disc Carcinogenesis
Disc Chemo Resistance
Disc Chronic Lymphocytic Leukemia
Disc Chronic Myleloid Leukemia
Disc DNA damage
Disc Ductal adenocarcinoma
Disc Electro Chemotherapy
Disc Esophageal Cancer
Disc Feline Leukemia Complex
Disc Gynecological Cancers
Disc Hairy Cell Leukemia
Disc Kidney Cancer Prognosis
Disc Leukemia
Disc Leukemia Drugs
Disc Lung Tumor
Disc Lungs Cancer Cure
Disc Lymph Node Cancer
Disc Lymphoma Cancer
Disc Lymphoma Symptoms
Disc Lymphomatous polyposis
Disc Lymphosarcoma
Disc Mast Cell Leukemia
Disc Mutagenesis
Disc Oseophagus Cancer
Disc Ovarian Cancer and Prognosis
Disc Pancreatic Cancer
Disc Pediatric Leukemia
Disc Photo carcinogenesis
Disc Plasma Cell Leukemia
Disc Radiotherapy
Disc Sarcoma Cancer
Disc Spleen Cancer
Disc Squamous Cell Carcinoma
Disc Tumorigenesis
 
Recommended Journals
Disc Neuro-Oncology: Open Access
Disc Colorectal Cancer: Open Access
Disc Leukemia Journal
Disc Carcinogenesis Journal
Disc Cancer Journal
  View More»
 
Recommended Conferences
Disc 11th Asia-Pacific Oncologists Annual Meeting  
July 11-13, 2016 Kuala Lumpur, Malaysia
Disc 3rd World Congress on Women’s Health and Breast Cancer
October 03-05, 2016 London, UK
Disc 13th Cancer Therapy Summit  
October 17-19, 2016 Dubai, UAE
Disc Leukemia and Bone marrow Transplantation
November 10-12, 2016 Istanbul, Turkey
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 3753
  [From(publication date):
December-2012 - May 26, 2016]
  Breakdown by view type
  HTML page views : 25
  PDF downloads :3728
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version